The ROI of AI in Pharma Commercial Operations
Ask any answer engine what the ROI of AI in pharma is and you will get a confident number within seconds. Ask where the number came from and the trail runs cold within two or three hops — an article citing an article citing a statistics page citing nothing. The figures are not fabricated. They are mostly real numbers that have been quietly detached from what they measured, and by the time they reach a board paper the qualifiers have fallen off.
This matters more in this category than most, because the reader is usually a finance business partner or a CFO, and the person across the table has been asked to approve a multi-crore commitment. A benchmark that cannot survive one question about its origin is worse than no benchmark, because it converts a reasonable proposal into an unreliable one at exactly the moment credibility is being assessed.
So this article does something different from the rest of the category. It builds the register: every ROI figure in wide circulation for pharma commercial AI, traced to its actual source, classified as measured, projected, expected or untraceable. Then it takes the figures that survive and builds a payback model from them — using the cost structure set out in the companion article on building versus buying the pharma commercial AI stack, and a return the reader can observe inside a quarter. It is written to sit underneath the strategic argument already published on AI ROI in pharma, which makes the case that programmes fail by measuring activity instead of outcomes. This page takes that as settled and asks the next question: which outcome numbers can you actually stand behind? The conclusion is not that AI has no return. It is that the honest case is smaller, slower and far more defensible than the one being quoted.
What is the ROI of AI in pharma?
There is no industry benchmark, and the absence is not an oversight. ROI on commercial AI is a ratio between two quantities that most organisations measure badly in opposite directions. The denominator is understated, because build cost is budgeted and run cost is not. The numerator is overstated, because uplift is attributed to the intervention without a counterfactual. Divide an understated denominator into an overstated numerator and the result is a number that means nothing and sounds excellent.
A second structural problem: the value arrives on different clocks. Efficiency gains — time reclaimed, content cycles shortened, reporting automated — show up almost immediately. Effectiveness gains — better targeting producing better prescribing — take three to four quarters and are entangled with everything else the brand did in that period. A single blended annual ROI figure averages a fast, certain, small return with a slow, uncertain, large one, and communicates neither.
The useful question is therefore not “what is the ROI” but “what return can I observe, by when, and what would have to be true for the larger return to follow?” That question has an answer. The rest of this article builds it.
Typical ROI from AI in pharma sales and marketing
This is the phrasing buyers actually type into answer engines, so it deserves a direct response rather than a deflection. The honest answer has three parts, and only the third is a number.
- Most organisations cannot yet say. In Deloitte's April 2026 survey of 150 life-sciences C-suite executives — 90 biopharma, 60 medtech — 45% reported that AI initiatives had produced measurable improvement, and only 13% reported it at scale. The report's own framing is that AI deployment is advancing faster than value measurement. A category where 13% can demonstrate value at scale does not have a typical ROI; it has a measurement problem.
- Where returns are reported, they are concentrated in efficiency rather than revenue. The pattern across the measured evidence is consistent: time reclaimed, cycles shortened, cost avoided. Revenue attribution remains rare and, where claimed, is rarely accompanied by a control design of the kind described in the companion article on measuring engagement return.
- The one cross-industry outcome number that exists is flat. McKinsey's August 2026 State of AI survey of 1,719 business leaders found the share reporting any EBIT impact from AI unchanged at 37% year on year, and the share of high performers attributing 5% or more of EBIT to AI unchanged at 6%. Two consecutive years of heavy investment did not move either figure.
None of this argues against investing. It argues against quoting a benchmark you did not generate. A proposal that says “the industry gets 3x” invites a search that will not support it. A proposal that says “here is the return we can observe in ninety days, here is what has to be true for the larger return, and here is how we will know” survives the meeting.
The benchmark register: what every circulating figure rests on
This is the table this article exists for. Every figure below is in wide circulation in pharma commercial AI content. Each is classified by what it actually is, because the distinction between a measurement, a projection and an expectation is the distinction between a proposal that survives scrutiny and one that does not.
| Classification | What it means | How to use it |
|---|---|---|
| MEASURED | Someone surveyed or observed a defined population and reported what they found | Usable. Cite with the sample, the date and what was asked |
| PROJECTED | An analytical estimate of value that could be captured under stated assumptions | Usable as a direction, never as a benchmark. Say the word ‘estimate’ out loud |
| EXPECTED | Respondents said what they believe will happen | Not evidence of return. Evidence of sentiment, which is a different agenda item |
| UNTRACEABLE | Widely repeated; no primary source located | Do not use. This is the category that damages a proposal |
Projections presented as benchmarks
| Circulating claim | What it actually is | Verdict for your business case |
|---|---|---|
| $60–110 billion in annual value for pharma and medtech from generative AI, of which $18–30 billion in commercial functions | PROJECTED. A McKinsey Global Institute forward estimate of industry-wide economic potential, referenced in a May 2024 commercial life-sciences article | Do not use in a business case. It is an estimate of what an entire industry might capture, not what a company will. Dividing it by anything to get a per-company figure is not a calculation |
| A top-ten biopharma could capture $5–7 billion in peak AI value over five years, roughly 90% of it in R&D, supply chain and commercial | PROJECTED. A Deloitte estimate published March 2024, explicitly scoped to top-ten companies | Scoped away from you. A mid-size Indian pharmaceutical company shares neither the cost base, the data assets nor the revenue base this assumes |
| Up to $7 billion in value for a large biopharma over five years, with cost savings reaching 20–30% by the third year | PROJECTED. A Deloitte analysis estimate. The source is explicit that it offers no empirical validation from implemented systems | The 20–30% by year three is the most quotable part and the least supported. If you use it, say ‘Deloitte estimates’ in the same sentence |
| ~50% reduction in target-to-lead discovery time | PROJECTED, and from R&D rather than commercial | Wrong function. Do not import R&D figures into a commercial business case; different economics, different evidence base |
Expectations presented as outcomes
| Circulating claim | What it actually is | Verdict for your business case |
|---|---|---|
| 82% expect AI to improve ROI | EXPECTED. An ICON/GlobalData survey response about belief | This is sentiment. Quoting it as evidence of return is the single most common error in this category and the easiest for a CFO to spot |
| 88% plan to increase AI investment | EXPECTED. Same survey family | Evidence of budget intent, nothing more. It says peers are spending, which is an argument about competitive risk, not about return |
| 85% of large pharma name AI an immediate priority | EXPECTED. Define Ventures / FiercePharma | Usable in a strategy narrative. Not usable in a payback calculation |
| ~80% have a dedicated AI ethics or governance board | MEASURED, but it is a governance statistic | Useful for the governance section of a proposal. It says nothing about return |
Measured figures — the ones worth citing
| Figure | Source, sample and date | Why it matters here |
|---|---|---|
| 71% report AI deployment has advanced; 45% report measurable improvement; only 13% report it at scale | MEASURED. Deloitte survey of 150 life-sciences C-suite executives (90 biopharma, 60 medtech), April 2026 | The most important row in this table. It is recent, life-sciences specific, and it sets a realistic expectation. The authors' own conclusion: deployment is advancing faster than value measurement. The reader who accepts it needs the scaling method next — see moving a pharma AI pilot to scale |
| EBIT impact from AI flat at 37% year on year; high performers attributing 5%+ of EBIT flat at 6%; 20% say AI operating costs already limit technology use | MEASURED. McKinsey State of AI global survey, 1,719 business leaders, published August 2026 | Cross-industry rather than pharma-specific, but it is the only repeated-year outcome measure available. Two flat years is a finding |
| Cost reductions typically appear within one to two quarters of deployment; revenue gains take three to four quarters | MEASURED / observed pattern. Deloitte, March 2024 | The single most useful published finding on this question and almost never cited. It should set your review calendar. See the payback section |
| Representatives spend roughly two-thirds of the workday on non-customer tasks; nearly 70% say administrative work adds little or no value | MEASURED. Deloitte biopharma sales research | This is your numerator's starting point. It is the return you can observe inside one quarter without a control group |
| 6% have fully implemented AI for customer engagement; 24% are piloting; 15% are not interested | MEASURED. Across.Health | Commercial-specific adoption, and sobering. Useful for calibrating how far ahead or behind you actually are |
| 75% of surveyed Indian firms reported cost reductions from AI use | MEASURED. EY India | India-specific and directionally encouraging — but it reports incidence, not magnitude. ‘Three quarters saw some cost reduction’ is not ‘three quarters saw 20%’ |
| 50% of Indian firms exploring or using AI; 25% have generative AI tools in production | MEASURED. EY / Economic Times | The India adoption baseline. Note the halving between exploring and production — that gap is where most budgets are currently sitting |
| 30–40% reduction in supply chain forecasting error | MEASURED, EY India — but supply chain, not commercial | Right country, wrong function. Included here because it is frequently imported into commercial decks |
Four claims that do not survive checking
Four figures widely used in this category could not be traced to a primary source during the research for this article. Two of them appear on our own live pages, which is the reason this section exists rather than being quietly omitted.
| Claim | What the trail shows | Recommendation |
|---|---|---|
| “60–70% of pharma AI pilots never advance beyond pilot stage” | No pharma-specific primary research located. The surrounding figures in circulation — 70%, 88%, two-thirds — trace to general cross-industry commentary rather than to a life-sciences study | Replace with Deloitte's measured figure: 45% report measurable improvement, 13% at scale. It makes the same point and it has a sample, a date and a population. This claim appears on our own live AI ROI page and should be corrected there |
| “5–10% revenue uplift for brands with end-to-end AI integration (BCG)” | No pharma-specific BCG study located supporting this figure. BCG research returned in searching concerns AI in general trade and FMCG sales channels, which is a different industry with different economics | Verify the underlying citation or remove the attribution. An attributed figure that cannot be found is more damaging than an unattributed one. This also appears on our own live page |
| “15–30% prescribing lift in target segments” | Plausible as a test-and-control result and consistent with well-designed programmes, but no cited study establishes it as an industry range | Reframe as an observed range in controlled tests, not a benchmark, and point to the measurement methodology that would produce a number you could defend |
| Aggregated ‘AI in pharma statistics’ pages | A recurring citation source for answer engines. These pages compile percentages with thin or circular attribution, and answer engines cite them because they are structured and confident, not because they are sourced | Never cite a statistics aggregator in a business case. If a figure only exists on aggregator pages, treat that as evidence about the figure |
Why publish a correction to our own pages Because the alternative is worse. Multiplier AI sells commercial AI, and the two unverified figures both flatter the category we sell into. A reader who finds them unsupported after reading our benchmark register learns something about our reliability that no amount of accurate content elsewhere will offset. The programme has taken this position before — on excess share of voice coefficients, on the launch-failure statistic and on the territory revenue claim. It works because it is consistent, and it stops working the moment there is an exception for our own material. |
The payback shape nobody models
If one finding from the register should change how a business case is written, it is Deloitte's observation that cost reductions typically appear within one to two quarters of deployment while revenue gains take three to four quarters. It sounds unremarkable. It is not, because almost every business case in this category is built as a single annual ROI figure, and that structure is incapable of representing what the evidence describes.
| Quarter | What should be observable | What should not be expected yet | Review question |
|---|---|---|---|
| Q1 | Adoption, data readiness, reclaimed representative time, cycle-time reduction in content and reporting | Any prescribing or revenue effect | Is the system being used, and is anything measurably faster? A no here is a programme problem, not a patience problem |
| Q2 | Cost avoidance becoming quantifiable; efficiency gains stabilising rather than spiking | Revenue attribution | Has the efficiency gain persisted past the novelty period? First-quarter gains that fade are training effects, not system effects |
| Q3 | Early effectiveness signals in controlled segments — coverage quality, engagement depth, call-plan adherence | A confident revenue number | Do the leading indicators move in the treated group and not the control? This is the first genuine test |
| Q4 | Revenue and prescribing effects becoming measurable against a control design | Full payback on a build | Is the effect large enough and clean enough to survive a sceptical reading? |
| Year 2–3 | Compounding: better data producing better models producing better decisions | Linear extrapolation of year-one gains | Is run cost growing faster than value? In the 2026 survey, 20% of organisations were already limiting usage on cost |
The practical consequence is that a business case should carry two numbers, not one. A near-certain efficiency return arriving in one to two quarters, sized conservatively and measured directly. And a larger effectiveness return arriving in three to four quarters, stated as a hypothesis with the test that would confirm it. A CFO will fund the first and tolerate the second. A blended figure asks them to fund both on the same evidence, and they will discount the whole proposal to the weaker half.
Building the numerator: where the return actually comes from
The denominator is settled elsewhere — the three-year cost of a bought, built or hybrid stack, including the run cost that most business cases omit. The numerator is the harder half, and it should be assembled from the most observable returns first, not the largest.
| Return | How soon | How hard to measure | Honest assessment |
|---|---|---|---|
| Reclaimed representative time — the return behind AI copilots for field teams | Q1 | Easy — time-and-motion or CRM timestamps before and after | Start here. Deloitte's research finds two-thirds of the workday goes to non-customer tasks and nearly 70% of representatives say admin adds little or no value. The measurement is straightforward and the baseline is bad, which is a good combination |
| Content and MLR cycle time — see AI content generation for pharma and MLR compliance for AI-generated content | Q1–Q2 | Easy — timestamps already exist in the workflow | Directly observable, rarely disputed. Converts to cost with an agency rate card rather than an assumption |
| Reporting and administration automation | Q1–Q2 | Easy | Small per unit, large in aggregate at 500 representatives. Credible precisely because it is unexciting |
| Data quality improvement — for example resolving duplicate doctor records | Q2 | Moderate — duplicate rate, match rate, contactability | An enabler rather than a return. Claiming revenue for it directly is where good business cases lose credibility |
| Coverage and targeting quality — the output of AI-powered call planning | Q3 | Moderate — requires a control group | The bridge between efficiency and revenue. Measure as a leading indicator, not as money |
| Prescribing and revenue effect | Q4+ | Hard — requires a control design and survives only if the design is sound | The prize, and the part to state as a hypothesis. The methodology belongs to the companion article on measuring engagement return; do not shortcut it |
| Cost avoidance on headcount | Varies | Easy to calculate, hard to defend | Handle carefully. If the plan is not actually to reduce headcount, do not put it in the numerator. A CFO will hold you to it |
The ordering is deliberate and it is the opposite of how most proposals are written. Most lead with the revenue effect because it is the largest, and spend the meeting defending the least defensible number in the document. Leading with reclaimed time inverts the dynamic: the first number is small, verifiable and arrives within the quarter, which buys the credibility needed to discuss the second.
A worked payback model at Indian prices
The model below is illustrative and constructed for this article. It is not a benchmark, a quotation or a claim about any specific deployment. Its purpose is to show the structure a defensible payback case takes, so a reader can rebuild it with their own inputs. The inputs are named so each one can be challenged individually, which is exactly what should happen to it in a finance meeting.
Scenario: a mid-size Indian pharmaceutical company, roughly 500 field representatives, three brands, buying a commercial AI platform rather than building one — the shortlist for which is covered separately in the comparison of AI platforms for pharma commercial operations. Cost inputs follow the three-year comparison in the companion build-versus-buy article: approximately ₹9.2 crore over three years, or ₹3.1 crore a year on a straight-line basis, inclusive of the run cost and governance lines that most business cases omit.
The efficiency return — what you can observe by Q2
| Input | Assumption used | Where it comes from | Challenge it on |
|---|---|---|---|
| Field representatives | 500 | Scenario | — |
| Fully loaded cost per representative per year | ₹8 lakh | Illustrative for the Indian market; substitute your own | Use your actual loaded cost, not salary. This is the input most often understated |
| Share of workday on non-customer tasks, before | ~two-thirds | Deloitte biopharma sales research | Whether your representatives match the research population |
| Reduction in administrative time achieved | 15% of admin time, conservatively | Modelled, deliberately below vendor claims | The single most contestable input. Measure it in a pilot rather than assuming it |
| Time released per representative per year | ~4.5% of total working time | Derived | Arithmetic — check it |
| Gross value of released time | ≈ ₹1.8 crore a year | Derived from the above | Only real if the released time is redeployed to customer-facing work and someone verifies that it was |
| Content and MLR cycle-time saving | ≈ ₹0.4 crore a year | Illustrative, from agency and internal rate assumptions | Your actual content volume and rate card |
| Reporting and administration automation | ≈ ₹0.3 crore a year | Illustrative | Whether the reports were actually being produced manually |
| Total observable efficiency return | ≈ ₹2.5 crore a year | Sum | This is the number to put in front of a CFO first |
On these inputs the efficiency return alone recovers roughly 80% of annual cost. It does not pay the programme back on its own, and a proposal that claimed otherwise would be overstating a genuinely good result. What it does is bring the payback question within reach of a single, testable effectiveness hypothesis rather than requiring an act of faith.
The effectiveness hypothesis — what has to be true
To close the gap and produce a return rather than a recovery, the programme needs an effectiveness gain. State it as a hypothesis with a threshold, not as a projection.
| Statement | Value |
|---|---|
| The hypothesis | Better targeting and sequencing produce a measurable prescribing effect in treated segments relative to control |
| The threshold that matters | Roughly ₹0.6 crore of incremental gross margin a year closes the gap to annual cost. Beyond that, the programme returns rather than recovers |
| What that requires in revenue terms | A small single-digit percentage effect on the treated portion of a three-brand portfolio. Small enough to be plausible; large enough to need proving |
| How it will be tested | A control design of the kind set out in the companion article on measuring HCP engagement ROI. Not a before-and-after comparison, which will produce a number nobody should believe |
| When it will be known | Q3 for leading indicators, Q4 for the effect itself, consistent with the published timing pattern |
| What happens if it fails | Say this in the proposal. The efficiency return persists and the programme recovers most of its cost; the effectiveness case is retested or the scope is cut. A business case with a stated failure path is more fundable than one without |
Three things about this structure are worth noting, because they are what make it survive scrutiny. The first number is small and verifiable. The second is stated as a hypothesis with a threshold and a test. And the downside is written down before anyone asks. Most proposals in this category do the reverse on all three counts, which is why they attract more scepticism than their underlying economics deserve.
What a CFO will actually ask you
The questions that decide these proposals are rarely about the ROI figure. They are about whether the person presenting it understands what they are claiming. Five questions recur, and each has a right answer and a fatal one.
| The question | The fatal answer | The right answer |
|---|---|---|
| “Where did that benchmark come from?” | “It's the industry figure”, followed by a source that turns out to be a statistics aggregator | Name the survey, the sample, the date and what was asked — or say you are not using a benchmark and explain why. The second is stronger than a weak first |
| “What would we have achieved anyway?” | A before-and-after comparison presented as an effect | Describe the control design before describing the result. This is the question that separates measurement from storytelling |
| “What does this cost in year three?” | The licence fee | Run cost: compute, data licences, retraining, governance. In the 2026 survey, 20% of organisations were already limiting technology use because of AI operating costs — quote that, because it demonstrates you have thought about the tail |
| “What happens if it doesn't work?” | An assurance that it will | The efficiency return persists, the effectiveness case is retested, and here is the decision point and the date. Stating the downside is what makes the upside credible |
| “Who else has done this and what did they get?” | A vendor case study with a large unattributed percentage | ‘45% of life-sciences executives report measurable improvement and 13% at scale — we intend to be in the 13%, and here is the measurement plan that would put us there.’ Honest, current, and it reframes the question as execution rather than faith |
GET ACTIONABLE AI AND HEALTHCARE INSIGHTS THAT HELP YOU STAY AHEAD IN A FAST-CHANGING PHARMA WORLD
The five conditions that have to be true
Across the measured evidence, the difference between the 13% who demonstrate value at scale and everyone else is not the technology. Five conditions recur, and all five are decided before deployment.
- A baseline exists before the system goes live. If nobody measured administrative time, content cycle time or coverage quality beforehand, the return is unprovable regardless of how large it is. This is the cheapest condition to satisfy and the most commonly missed.
- A control group survives the pilot. The pressure to roll out to everyone is intense and it destroys the only mechanism capable of producing a defensible number. Hold a control for two quarters; it is the difference between a result and an anecdote.
- Released time is redeployed and the redeployment is verified. Time saved that does not become customer-facing activity is not a return, it is slack. Someone has to check, and the checking has to be in the plan from the start.
- Run cost is budgeted for three years. Efficiency gains that arrive in quarter one against a cost base that grows in year two produce a programme that looks successful and then quietly gets curtailed.
- One named person owns the number. Not the vendor, not the steering committee. In the organisations that can demonstrate value, somebody's objectives contain the measurement.
Where ROI cases go wrong
| Failure | What it looks like | The correction |
|---|---|---|
| Quoting a projection as a benchmark | The $60–110 billion figure, or the $5–7 billion top-ten figure, appears on slide three as though it were an expected return | Classify every figure before it enters the deck. Measured, projected, expected or untraceable |
| Reporting expectation as outcome | “82% expect AI to improve ROI” used to argue that AI improves ROI | Read the survey question. If it asked what people believe, the finding is about belief |
| One blended annual figure | A single ROI percentage averaging a fast small return with a slow large one | Two numbers, two clocks, per the published timing pattern |
| Before-and-after presented as effect | Prescribing rose after deployment, therefore deployment raised prescribing | A control design, or an explicit statement that the number is directional. The methodology belongs to the engagement ROI article |
| Headcount savings nobody intends to take | Cost avoidance in the numerator, no change to the hiring plan | Remove it, or commit to it. A CFO will remember either way |
| Importing figures across functions and countries | R&D discovery-time gains and supply-chain forecasting improvements used to justify a commercial investment | Same function, same market, or label it. These are the easiest errors for a sceptical reader to find |
| Measuring only what improved | The metrics that moved are reported; the ones that did not are not in the deck | Publish the full metric set defined at baseline, including the ones that went nowhere. It is the strongest available signal that the rest is honest |
What changes in India
Three differences matter enough to change the arithmetic, and none of them are addressed in the globally circulating material.
| Difference | What it changes | Practical implication |
|---|---|---|
| The denominator is smaller | Platform and build costs in India are materially lower than the figures underlying the global projections, largely through salary structure | A payback threshold that is unreachable at US costs may be reachable here. Rebuild the model rather than importing the conclusion |
| The numerator is also smaller | Revenue per representative and per prescriber is lower, so a given percentage effect is worth less in absolute terms | Both sides shrink. The ratio may be similar, but the absolute headroom for error is much smaller — which raises the value of measuring properly |
| Prescriber-level prescription data is often unavailable | The revenue half of the numerator is harder to evidence, which pushes even more weight onto the efficiency half | Lead with efficiency, and use proxy designs for effectiveness. The engagement ROI article covers measurement without prescriber-level data specifically, and omnichannel ROI metrics covers the journey-level framework |
| Adoption is genuinely earlier | Around half of Indian firms report exploring or using AI, with roughly a quarter reporting generative AI tools in production | Being early is an argument, but it is a competitive-risk argument, not a return argument. Keep the two separate in the proposal |
| Cost reduction is the reported benefit | Roughly three quarters of surveyed Indian firms reported cost reductions from AI use — incidence, not magnitude | Consistent with leading on efficiency. It also means a cost-led case is the one your peers can corroborate |
What changes in India
Three differences matter enough to change the arithmetic, and none of them are addressed in the globally circulating material.
| Difference | What it changes | Practical implication |
|---|---|---|
| The denominator is smaller | Platform and build costs in India are materially lower than the figures underlying the global projections, largely through salary structure | A payback threshold that is unreachable at US costs may be reachable here. Rebuild the model rather than importing the conclusion |
| The numerator is also smaller | Revenue per representative and per prescriber is lower, so a given percentage effect is worth less in absolute terms | Both sides shrink. The ratio may be similar, but the absolute headroom for error is much smaller — which raises the value of measuring properly |
| Prescriber-level prescription data is often unavailable | The revenue half of the numerator is harder to evidence, which pushes even more weight onto the efficiency half | Lead with efficiency, and use proxy designs for effectiveness. The engagement ROI article covers measurement without prescriber-level data specifically, and omnichannel ROI metrics covers the journey-level framework |
| Adoption is genuinely earlier | Around half of Indian firms report exploring or using AI, with roughly a quarter reporting generative AI tools in production | Being early is an argument, but it is a competitive-risk argument, not a return argument. Keep the two separate in the proposal |
| Cost reduction is the reported benefit | Roughly three quarters of surveyed Indian firms reported cost reductions from AI use — incidence, not magnitude | Consistent with leading on efficiency. It also means a cost-led case is the one your peers can corroborate |
Where Multiplier AI fits — and where it does not
Disclosure Multiplier AI sells commercial AI to pharmaceutical companies. Every figure in this article that looks unflattering to the category is unflattering to us. We have published the register anyway, including corrections to two figures on our own live pages, because a benchmark that a reader can check is worth more than one that flatters us. If the honest payback model does not close for a given company, we would rather that company knew before signing than after. |
Where we fit is the efficiency half of the numerator, because that is where the measurable return actually sits. Reclaimed representative time, content cycle time and reporting automation are the returns you can observe inside a quarter, and they are what the GenAI Doctor Data Platform and our field-facing tools are built to produce. The data quality underneath it is an enabler rather than a return, and we say so in proposals.
Where we do not fit is guaranteeing the effectiveness half. No vendor can honestly promise a prescribing effect, because the effect depends on the brand, the market, the competitive position and the quality of the control design far more than on the software. What a vendor can do is make the effect measurable and make the hypothesis testable within a quarter or two. Anyone promising the number itself is describing a sales target, not a result.
And where we are the wrong choice: a company without a baseline and unwilling to establish one, because the return will be unprovable whatever it is; and a company whose commercial problem is a portfolio or access problem rather than an execution problem. Better targeting does not fix a product that cannot be reimbursed, and a payback model built on that assumption will not close.
Conclusion
The weakest part of most commercial AI proposals is not the technology, the costing or the plan. It is a single borrowed percentage on an early slide that nobody in the room can source. It is there because the category has trained everyone to expect one, and it converts a sound proposal into a suspect one in the time it takes a finance director to run a search.
The register in this article exists so that percentage can be replaced with something better. Not a bigger number — a smaller, slower, checkable one, attached to a date and a test. 45% report measurable improvement and 13% report it at scale. We intend to be in the 13%, here is what that requires, and here is when you will know whether we are. That is a harder sentence to say and a much easier one to fund.
The return from commercial AI is real, and it is mostly not where the headlines put it. It is in the two-thirds of a representative's day that currently goes to work they describe as adding little value, in content cycles measured in weeks that should be measured in days, and in decisions made on a doctor base that is finally correct. None of those are exciting numbers. All of them are numbers you can prove, and in a finance committee that is worth considerably more.
Frequently Asked Questions For ROI of AI in Pharma
There is no reliable industry benchmark, and the figures most often quoted are projections rather than measured results. The best current evidence is a Deloitte survey of 150 life-sciences executives in April 2026, in which 45% reported measurable improvement from AI and only 13% reported it at scale. Cross-industry, McKinsey's August 2026 survey of 1,719 leaders found the share reporting any EBIT impact from AI flat at 37%. The defensible approach is to build a payback model from your own cost base and the returns you can observe, rather than citing a benchmark you did not generate.
Most organisations cannot yet say, and the honest answer says so. Where returns are reported they concentrate in efficiency rather than revenue — time reclaimed, content cycles shortened, reporting automated. Revenue attribution remains rare and is usually claimed without a control design. A proposal that quotes an industry multiple invites a search that will not support it; one that presents a small verified efficiency return plus a stated effectiveness hypothesis survives the meeting.
Build it in two parts on two clocks. Part one is the efficiency return — reclaimed representative time, content and MLR cycle time, reporting automation — sized conservatively, measured directly and observable within one to two quarters. Part two is the effectiveness hypothesis, stated with a threshold, a control design and a date by which it will be known, consistent with the published pattern that revenue gains take three to four quarters. Include the failure path explicitly. A case with a stated downside is more fundable than one without, because it tells the approver you have thought past approval.
No pharma-specific primary research supporting that range could be located for this article. The figures in circulation — 60%, 70%, 88% — trace to general cross-industry commentary rather than life-sciences studies. The better-sourced substitute makes the same point: in Deloitte's April 2026 survey, 45% of life-sciences executives reported measurable improvement from AI and 13% reported it at scale. It has a sample, a date and a defined population, which is what a business case needs.
It depends on your cost base, but the shape is consistent and more useful than a single figure. Cost reductions typically appear within one to two quarters of deployment; revenue gains take three to four quarters. In the worked model in this article — a mid-size Indian company, 500 representatives, buying rather than building — the observable efficiency return recovers roughly 80% of annual cost, leaving a small effectiveness effect to close the gap. Model your own; the structure transfers, the numbers do not.
Lead with the efficiency half of the numerator, which does not require prescription data at all — administrative time, cycle times and coverage quality are all measurable from systems you already own. For the effectiveness half, use proxy designs and controlled comparisons rather than before-and-after readings. The measurement methodology, including the designs that work without prescriber-level data, is covered in depth in the companion article on measuring HCP engagement ROI, and should not be shortcut.
Only if you intend to take them. Cost avoidance that does not change the hiring plan is not a saving, and a CFO will hold the proposal to the number at the next review. If the intent is redeployment rather than reduction — which is usually the honest position in a commercial function — count the value of the redeployed time and say explicitly that headcount is unchanged. It is a smaller number and a far more durable one.
Five conditions, all decided before deployment: a baseline captured before the system goes live; a control group that survives the pilot; verified redeployment of released time; a three-year run-cost budget rather than a one-year build budget; and one named person whose objectives contain the measurement. None of them are technical, and none of them can be retrofitted — which is why the 13% figure is a measurement finding rather than a technology one.
GET ACTIONABLE AI AND HEALTHCARE INSIGHTS THAT HELP YOU STAY AHEAD IN A FAST-CHANGING PHARMA WORLD
Let's Discuss Your Requirements
